BioSpace News Archive

Prime Medicine, Inc. announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences:

Icosavax, Inc. today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023.

Rhythm Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s orphan drug designation request for setmelanotide as a treatment for acquired hypothalamic obesity,

scPharmaceuticals Inc. today announced that the Company has received positive feedback from the U.S. Food and Drug Administration (FDA) on two key long-term growth initiatives.

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today provided a regulatory update on Buprenorphine Buccal Film, for which an abbreviated new drug application (“ANDA”) has been filed with the U.S. Food and Drug Administration (“FDA” or the “Agency”) by its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”).

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced significant updates to its foundational IP portfolio.

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ) today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ (“CELZ-201-DDT”).

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO ® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors.

10x Genomics, Inc., a leader in single cell and spatial biology, announced that the European Unified Patent Court issued a preliminary injunction against NanoString Technologies, Inc. for infringing European Patent 4 108 782 B1.

ChoiceSpine LLC, a privately held spinal device company held by Altus Capital Partners in Knoxville, TN, is pleased to announce today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the Blackhawk® Ti 3D Printed Cervical Spacer System with standalone clearance.